|Articles|July 13, 2020

COVID-19 Could Raise HIV, TB, Malaria Death Rates

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

The disruptions caused by the COVID-19 pandemic and its response could cause a surge in HIV, malaria, and tuberculosis (TB) deaths, according to a new modeling study published in The Lancet Global Health by authors from Imperial College London.

While concern has been raised about the relationship between these disruptions and other health priorities before, the new model focuses on where the worst impact would be felt: low- and middle-income countries. Their modeling seems to suggest that at current pace HIV, TB, and malaria deaths could increase by as much as 10%, 20%, and 36% respectively over the next 5 years due to the disruption of health services.

The models indicate that the stability of programs which address long standing infectious disease health burdens are at risk. In areas with substantial prior health care resource strains, the authors even note that years of life lost (defined as the number of years a person would have been expected to live had they not died of a particular cause) could in some cases be of similar scale to the biological impact of the pandemic itself. The COVID-19 pandemic has caused substantial disruptions by overwhelming struggling health systems, and through lockdown measures limiting routine health care activity and patient care-seeking. The demobilization of many sectors of industry has also lead to interruptions in medical supply chains.

The authors went on to explain that bolstering “access to antiretroviral therapy (ART), timely TB diagnosis and treatment, and early resumption of the distribution of long-lasting insecticide-treated nets and antimalarial treatment” could mitigate negative health impacts, according to a press release.

For more on this story, Contagion spoke with co-lead author Professor Timothy Hallett of Imperial College London, UK. Hallett was careful to clarify that predicting the future impact of the ongoing COVID-19 pandemic is challenging, including due to ongoing uncertainty around the novel virus itself.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.